World Health Organization. Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern, https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (2021).

ECDC. SARS-CoV-2 Variants Dashboard, https://www.ecdc.europa.eu/en/covid-19/situation-updates/variants-dashboard (2022).

CDC. COVID Data Tracker, https://covid.cdc.gov/covid-data-tracker/#variant-proportions (2022).

Yu, X. et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discov. 8, 4 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Jacobsen, H. et al. Diminished neutralization responses towards SARS-CoV-2 Omicron VoC after mRNA or vector-based COVID-19 vaccinations. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.21.21267898v1 (2021).

Cele, S. et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature 602, 654–656 (2022).

Article  PubMed  Google Scholar 

Basile, K. et al. Improved neutralisation of the SARS-CoV-2 Omicron variant following a booster dose of Pfizer-BioNTech (BNT162b2) COVID-19 vaccine. Viruses 14, 2023 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Ikemura, N. et al. SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.13.21267761v1 (2021).

Lu, L. et al. Neutralization of severe acute respiratory syndrome coronavirus 2 omicron variant by sera from BNT162b2 or coronaVac vaccine recipients. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciab1041 (2021).

Article  PubMed  PubMed Central  Google Scholar 

Nemet, I. et al. Third BNT162b2 vaccination neutralization of SARS-CoV-2 omicron infection. N. Engl. J. Med. 386, 492–494 (2021).

Article  PubMed  Google Scholar 

Gruell, H. et al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 28, 477–480 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Dejnirattisai, W. et al. Reduced neutralisation of SARS-CoV-2 Omicron B.1.1.529 variant by post-immunisation serum. Lancet 399, 234–236 (2022).

Article  PubMed  Google Scholar 

Schmidt, F. et al. Plasma neutralization of the SARS-CoV-2 Omicron variant. N. Engl. J. Med. 386, 599–601 (2021).

Article  PubMed  Google Scholar 

Cameroni, E. et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature 602, 664–670 (2022).

Article  PubMed  Google Scholar 

Pajon, R. et al. SARS-CoV-2 Omicron variant neutralization after mRNA-1273 booster vaccination. N. Engl. J. Med. 386, 1088–1091 (2022).

Article  PubMed  Google Scholar 

Planas, D. et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature 602, 671–675 (2022).

Article  PubMed  Google Scholar 

Liu, L. et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature 602, 676–681 (2022).

Article  PubMed  Google Scholar 

Zeng, C. et al. Neutralization and stability of SARS-CoV-2 Omicron variant. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.16.472934v1 (2021).

Zhao, X. et al. Reduced sera neutralization to Omicron SARS-CoV-2 by both inactivated and protein subunit vaccines and the convalescents. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.16.472391v1 (2021).

Carreño, J. M. et al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature 602, 682–688 (2022).

Article  PubMed  Google Scholar 

Syed, A. M. et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. Proc. Natl Acad. Sci. USA 119, e2200592119 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Dolzhikova, I. et al. Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.17.21267976v1 (2021).

Ai, J. et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microbes Infect. 11, 337–343 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Edara, V. V. et al. mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-CoV-2 Omicron variant. Cell Rep. Med. 3, 100529 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Ariën, K. K. et al. Three doses of BNT162b2 vaccine confer neutralising antibody capacity against the SARS-CoV-2 Omicron variant. npj Vaccines 7, 35 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Muik, A. et al. Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera. Science 375, 678–680 (2022).

Article  PubMed  Google Scholar 

Lusvarghi, S. et al. SARS-CoV-2 Omicron neutralization by therapeutic antibodies, convalescent sera, and post-mRNA vaccine booster. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.22.473880v1 (2021).

Wang, K. et al. Memory B cell repertoire from triple vaccinees against diverse SARS-CoV-2 variants. Nature https://doi.org/10.1038/s41586-022-04466-x (2022).

Zhou, R. et al. Vaccine-breakthrough infection by the SARS-CoV-2 Omicron variant elicits broadly cross-reactive immune responses. Clin. Transl. Med. 12, e720 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Hu, J. et al. Increased immune escape of the new SARS-CoV-2 variant of concern Omicron. Cell. Mol. Immunol. 19, 293–295 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Wang, X. et al. Homologous or heterologous booster of inactivated vaccine reduces SARS-CoV-2 Omicron variant escape from neutralizing antibodies. Emerg. Microbes Infect. 11, 477–481 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Tada, T. et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. eBioMedicine https://doi.org/10.1016/j.ebiom.2022.103944 (2022).

Pérez-Then, E. et al. Immunogenicity of heterologous BNT162b2 booster in fully vaccinated individuals with CoronaVac against SARS-CoV-2 variants Delta and Omicron: The Dominican Republic Experience. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.27.21268459v1 (2021).

Miyamoto, S. et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants. Med 3, 249–261.e244 (2022).

Article  PubMed  Google Scholar 

van Gils, M. J. et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. PLoS Med. 19, e1003991 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Tan, C. S. et al. Homologous and heterologous vaccine boost strategies for humoral and cellular immunologic coverage of the SARS-CoV-2 omicron variant. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.02.21267198v2 (2021).

Kotaki, R. et al. Two doses of mRNA vaccine elicit cross-neutralizing memory B-cells against SARS-CoV-2 Omicron variant. Preprint at https://www.biorxiv.org/content/10.1101/2021.12.24.474091v1 (2021).

Willett, B. J. et al. SARS-CoV-2 Omicron is an immune escape variant with an altered cell entry pathway. Nat. Microbiol. 7, 1161–1179 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Kitchin, D. et al. Ad26.COV2.S breakthrough infections induce high titers of neutralizing antibodies against Omicron and other SARS-CoV-2 variants of concern. Preprint at https://www.medrxiv.org/content/10.1101/2021.11.08.21266049v3 (2022).

Wang, Y. et al. Resistance of SARS-CoV-2 omicron variant to convalescent and CoronaVac vaccine plasma. Emerg. Microbes Infect. 11, 424–427 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Cheng, S. M. S. et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med 28, 486–489 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Banerjee, A. et al. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, beta, delta, and omicron variants. Med 3, 422–432.e423 (2022).

Article  PubMed  Google Scholar 

Lyke, K. E. et al. SARS-CoV-2 Omicron neutralization after heterologous vaccine boosting. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.13.22268861v1 (2022).

Cheng, S.-H., Lin, Y.-C., Chen, C.-P. & Cheng, C.-Y. Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222. Preprint at https://www.medrxiv.org/content/10.1101/2021.12.10.21267574v2 (2022).

Liu, J. et al. Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron. Nature 603, 493–496 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Kaabi, N. A. et al. Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: A phase 2 trial. Signal Transduct. Target. Ther. 7, 172 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Xia, H. et al. Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. Cell Host Microbe 30, 485–488.e483 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Lapa, D. et al. Retention of neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V-vaccinated individuals. Vaccines 10, 817 (2022).

Article  PubMed  PubMed Central  Google Scholar 

Seki, Y. et al. Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants. Med 3, 406–421.e404 (2022).

Article  PubMed  Google Scholar 

Furukawa, K. et al. Acquired neutralizing breadth against SARS-CoV-2 variants including Omicron after three doses of mRNA COVID-19 vaccination and the vaccine efficacy. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.25.22269735v2 (2022).

Girard, B. et al. mRNA-1273 Vaccine-elicited neutralization of SARS-CoV-2 Omicron in adolescents and children. Preprint at https://www.medrxiv.org/content/10.1101/2022.01.24.22269666v1 (2022).

Gupta, S. L. et al. Loss of Pfizer (BNT162b2) vaccine-induced antibody responses against the SARS-CoV-2 Omicron variant in adolescents and adults. J. Virol. 96, e00582–00522 (2022).

Article  PubMed Central  Google Scholar 

Chen, L.-L. et al. Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine. Emerg. Microbes Infect. 11, 543–547 (2022).

Article  PubMed  PubMed Central  Google Scholar